Latest Infant Formula News

Page 1 of 5
Nuchev lifted FY26 revenue 12% to A$25.7 million, but a wider loss, weaker margins and heavier cash use have left the wellness group dependent on shareholder-backed funding. Post-year-end drawdowns reduced its available working-capital headroom to A$750,000.
Victor Sage
Victor Sage
20 Nov 2026
The a2 Milk Company says China-label infant formula offtake has recovered to about half of pre-disruption levels, but expects total IMF sales to remain broadly flat in FY27. Group revenue and EBITDA are still forecast to grow, with earnings heavily weighted to the second half.
Victor Sage
Victor Sage
19 Nov 2026
Clover Corporation has entered FY27 with stronger margins, no interest-bearing debt and revenue momentum after reporting a 50% rise in FY26 NPAT. The company expects first-half FY27 revenue of about $60 million and says full-year revenue and earnings could outperform FY26 if current conditions persist.
Victor Sage
Victor Sage
17 Nov 2026
Nutritional Growth Solutions has cut quarterly net operating cash outflow by 54% while completing its Sprout Organic acquisition just after quarter end. The enlarged group starts with US$1.613 million in cash, no borrowings and a substantially larger share base.
Victor Sage
Victor Sage
30 Oct 2026
Bubs Australia has expanded its US footprint to more than 12,000 stores after securing permanent FDA authorisation, but quarterly revenue fell 9.8% and operating cash outflow increased. The company ended September with A$13.4 million of available liquidity, equivalent to 2.2 quarters at the reported cash-burn rate.
Victor Sage
Victor Sage
29 Oct 2026
Australian Dairy Nutritionals reported a 54% year-on-year revenue fall in the September quarter and held just A$513,000 in cash against a A$619,000 operating cash outflow. The infant formula group is pursuing a A$500,000 placement and a broader capital raise as it waits for China distribution growth and Vietnam sales to rebuild momentum.
Victor Sage
Victor Sage
14 Oct 2026
Bubs Australia delivered 9.2% revenue growth and a sharp underlying EBITDA improvement in FY26, but statutory losses, weaker margins and negative operating cash flow expose the cost of its expansion. Permanent US FDA authorisation removes a major regulatory hurdle, while the annual report still flags material uncertainty around ongoing funding and cash generation.
Victor Sage
Victor Sage
14 Oct 2026
Nutritional Growth Solutions has completed its acquisition of Sprout Organic, installing founder Selasi Berdie as CEO and reshaping the group around infant, toddler and children’s nutrition. The deal lifts shares on issue to 964 million, while management targets A$870,000 in annualised savings.
Victor Sage
Victor Sage
1 Oct 2026
Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.
Victor Sage
Victor Sage
10 Sept 2026
Australian Dairy Nutritionals reported a 47% reduction in net loss for FY26, driven by a 66% revenue jump in its nutritional powders segment, which now makes up 70% of total revenue.
Victor Sage
Victor Sage
27 Aug 2026
The a2 Milk Company posted a 12.4% rise in FY26 revenue to NZ$1.975 billion, but net profit from continuing operations fell 5.8% amid supply chain disruptions in China. The company declared a $300 million special dividend and expects mid single-digit revenue growth in FY27.
Victor Sage
Victor Sage
17 Aug 2026
Kingfish Limited outperformed the S&P/NZX50G with an 8.7% gross portfolio return in Q2 2026, driven by strong results from Fisher & Paykel Healthcare, Vista Group, and Infratil, while a2 Milk faced supply chain and regulatory challenges.
Victor Sage
Victor Sage
20 July 2026

Browse the archive

Full archive